Viridian Therapeutics Files Proxy Materials

Ticker: VRDN · Form: DEFA14A · Filed: Jun 10, 2024 · CIK: 1590750

Sentiment: neutral

Topics: proxy-statement, corporate-governance, filing-update

TL;DR

Viridian (formerly Miragen/Signal) filed more proxy docs. Standard stuff.

AI Summary

Viridian Therapeutics, Inc. filed a Definitive Additional Materials proxy statement on June 10, 2024. This filing relates to the company's proxy materials, which were previously filed. The company was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.

Why It Matters

This filing indicates that Viridian Therapeutics is proceeding with its shareholder communication and governance processes, which are essential for corporate decision-making and regulatory compliance.

Risk Assessment

Risk Level: low — This is a routine filing of additional proxy materials, not indicating any new or significant corporate events.

Key Players & Entities

FAQ

What is the purpose of this DEFA14A filing?

This filing is for Definitive Additional Materials related to Viridian Therapeutics, Inc.'s proxy statement, indicating it's supplementary information to previously filed proxy materials.

When was this filing made?

The filing was made on June 10, 2024.

What were Viridian Therapeutics' former names?

Viridian Therapeutics, Inc. was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.

What is the company's primary business classification?

The company is classified under Standard Industrial Classification code 8071, which is SERVICES-MEDICAL LABORATORIES.

Where is Viridian Therapeutics, Inc. located?

The company's business and mailing address is 221 Crescent Street, Bldg. 17, Suite 401, Waltham, MA 02453.

Filing Stats: 2,541 words · 10 min read · ~8 pages · Grade level 12.9 · Accepted 2024-06-10 08:05:27

Filing Documents

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 VIRIDIAN THERAPEUTICS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. On April 26, 2024, Viridian Therapeutics, Inc. (we, us, our, Viridian or the Company) filed a definitive proxy statement on Schedule 14A (the Proxy Statement) with the Securities and Exchange Commission in connection with our 2024 Annual Meeting of Stockholders to be held virtually on June 17, 2024 at 3:00 p.m. Eastern Time, or at any other time following adjournment or postponement thereof. This supplement (the Supplement) should be read in conjunction with the Proxy Statement. Viridian Therapeutics, Inc. Definitive Additional Materials ("Supplement") 2024 Annual Meeting of Stockholders June 2024 Cautionary note regarding forward-looking statements This Supplement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: our planned equity usage and employee compensation; execution upon our corporate goals and the delivery of catalysts; that without the Share Increase, we anticipate running out of equity to grant from our pool as soon as the first quarter of 2025; anticipated dilution, plan cost and shareholder value transferof the Share Increase; that we currently expect the Share Increase will be sufficient to meet our expected needs for approximately one year based on our historical grant practices and performance; and that we do not expect to grant annual employee awards in 2024, and therefore we anticipate a lower burn rate in 2024 compared to 2023. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including those risks set forth under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on May 8, 2024 and our other subsequent disclosure documents filed with the SEC. The forward-looking statements in this Supplement represent our views as of the date of this Supplement. Neither we, nor our affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Supplement. 2 Proposals for the 2024 Annual Meeting of Stockholders On April 26, 2024, Viridian Therapeutics, Inc. ("we," "us," "our," "Viridian" or the "Company") filed a definitive proxy statement on Schedule 14A (the "Proxy Statement") with the Securities and Exchange Commission in connection with our 2024 Annual Meeting of Stockholders to be held virtually on June 17, 2024 at 3:00 p.m. Eastern Time (the "Annual Meeting"), or at any other time following adjournment or postponement thereof. This Supplement should be read in conjunction with the Proxy Statement. The proposals to be voted upon at the Annual Meeting are as follows: 1. To elect the two Class III director nominees named in the Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified. 2. To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. 3. To approve,

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing